SCHEMBL47302

SCHEMBL47302

CNC(=O)c1cc(F)ccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 11/20 0.84
MAPK9 P45984 9/20 0.84
PTK2 Q05397 6/20 0.84
ZAP70 P43403 1/20 0.56
MAPK1 P28482 2/20 0.56
MAPK3 P27361 1/20 0.56
FGFR1 P11362 2/20 0.55
CDC7 O00311 1/20 0.53
PLK4 O00444 1/20 0.53
CHEK1 O14757 1/20 0.53
AURKA O14965 1/20 0.53
DCLK1 O15075 1/20 0.53
PDPK1 O15530 1/20 0.53
DAPK3 O43293 1/20 0.53
DYRK3 O43781 1/20 0.53
JAK2 O60674 1/20 0.53
PRKD3 O94806 1/20 0.53
PAK4 O96013 1/20 0.53
CHEK2 O96017 1/20 0.53
EGFR P00533 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1232326 0.93 MAPK10 (0.83) MAPK10MAPK9PTK2ZAP70MAPK1
SCHEMBL12887672 0.92 MAPK10 (0.72) MAPK10MAPK9PTK2MAPK1MAPK3
Vs-4718 SCHEMBL47360 0.92 MAPK10 (1.00) MAPK10MAPK9PTK2MAPK1FGFR1
Vs-4718 SCHEMBL29381276 0.92 MAPK10 (1.00) MAPK10MAPK9PTK2MAPK1FGFR1
Vs-4718 SCHEMBL29493098 0.92 MAPK10 (1.00) MAPK10MAPK9PTK2MAPK1FGFR1
Vs-4718 SCHEMBL29478885 0.92 MAPK10 (1.00) MAPK10MAPK9PTK2MAPK1FGFR1
Vs-4718 SCHEMBL30354503 0.91 PTK2 (1.00) MAPK10MAPK9PTK2MAPK1FGFR1
SCHEMBL12901048 0.90 MAPK10 (0.71) MAPK10MAPK9PTK2FGFR1EGFR
SCHEMBL12887696 0.86 MAPK10 (0.72) MAPK10MAPK9PTK2ZAP70MAPK1
SCHEMBL1231883 0.85 MAPK10 (0.81) MAPK10MAPK9PTK2MAPK1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11564927-B2 Therapeutic compositions, combinations, and methods of use VERASTEM, INC. (US) 2023-01-31 US disclosed
US-20210030703-A1 USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2021-02-04 US disclosed
US-20200330471-A1 THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE RGCM SA LLC, AS PURCHASER AGENT 2020-10-22 US disclosed
US-20180177788-A1 THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE RGCM SA LLC, AS PURCHASER AGENT 2018-06-28 US disclosed
US-9580439-B2 Inhibitors of focal adhesion kinase THE SCRIPPS RESEARCH INSTITUTE (US) 2017-02-28 US disclosed
US-9580439-B2 Inhibitors of focal adhesion kinase THE SCRIPPS RESEARCH INSTITUTE (US) 2017-02-28 US disclosed
US-9580439-B2 Inhibitors of focal adhesion kinase THE SCRIPPS RESEARCH INSTITUTE (US) 2017-02-28 US disclosed
WO-2017004192-A1 THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE VERASTEM, INC. (US) 2017-01-05 WO disclosed
US-9505719-B2 Synthesis and use of kinase inhibitors VERASTEM, INC. (US) 2016-11-29 US disclosed
WO-2016109426-A1 ORAL DOSING REGIMEN OF A DUAL MTOR AND PI3 INHIBITOR VERASTEM, INC. (US) 2016-07-07 WO disclosed
US-20130281443-A1 INHIBITORS OF FOCAL ADHESION KINASE THE SCRIPPS RESEARCH INSTITUTE (US) 2013-10-24 US disclosed
US-8501763-B2 Inhibitors of focal adhesion kinase THE SCRIPPS RESEARCH INSTITUTE (US) 2013-08-06 US disclosed
US-8501763-B2 Inhibitors of focal adhesion kinase THE SCRIPPS RESEARCH INSTITUTE (US) 2013-08-06 US disclosed
US-8501763-B2 Inhibitors of focal adhesion kinase THE SCRIPPS RESEARCH INSTITUTE (US) 2013-08-06 US disclosed
WO-2012012139-A1 SYNTHESIS AND USE OF KINASE INHIBITORS PONIARD PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
WO-2012006081-A1 ORAL FORMULATION OF KINASE INHIBITORS PONIARD PHARMACEUTICALS, INC. (US) 2012-01-12 WO disclosed
US-20110046121-A1 INHIBITORS OF FOCAL ADHESION KINASE THE SCRIPPS RESEARCH INSTITUTE (US) 2011-02-24 US disclosed
US-20110046121-A1 INHIBITORS OF FOCAL ADHESION KINASE THE SCRIPPS RESEARCH INSTITUTE (US) 2011-02-24 US disclosed
US-20110046121-A1 INHIBITORS OF FOCAL ADHESION KINASE THE SCRIPPS RESEARCH INSTITUTE (US) 2011-02-24 US disclosed
WO-2008115369-A2 INHIBITORS OF FOCAL ADHESION KINASE THE SCRIPPS RESEARCH INSTITUTE (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046121-A1 INHIBITORS OF FOCAL ADHESION KINASE PTK2, CABLES1, TNK2 MAPK10 590/4885MAPK9 239/4885PTK2 1/4885
US-11564927-B2 Therapeutic compositions, combinations, and methods of use PTK2, CD274, PDCD1LG2 MAPK10 804/4885MAPK9 1136/4885PTK2 1/4885
US-20210030703-A1 USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS CD274, PDCD1, PDCD10 MAPK10 1805/4885MAPK9 3263/4885PTK2 4571/4885
US-20200330471-A1 THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE PTK2, CD274, PDCD1LG2 MAPK10 804/4885MAPK9 1136/4885PTK2 1/4885
US-20130281443-A1 INHIBITORS OF FOCAL ADHESION KINASE PTK2, CABLES1, TNK2 MAPK10 590/4885MAPK9 239/4885PTK2 1/4885
US-20180177788-A1 THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE PTK2, CD274, PDCD1LG2 MAPK10 804/4885MAPK9 1136/4885PTK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.